![]() |
市場調查報告書
商品編碼
1827709
2025年心臟節律器全球市場報告Cardiac Pacemakers Global Market Report 2025 |
近年來,心臟節律器市場穩定成長,預計2024年將達到47.3億美元,2025年將達到49.5億美元,複合年成長率為4.6%。預測期內的成長動力包括人口老化、心血管疾病發生率上升、人們對心律不整的認知和治療需求不斷增強、心律調節器創新研發投入不斷增加、醫療基礎設施不斷發展和醫療設備可及性不斷提升,以及監管機構對心律調節器新功能和技術的核准。
預計未來幾年心臟節律器市場將強勁成長,到 2029 年將達到 65 億美元,複合年成長率為 7.1%。預測期內的成長歸因於對導線耐用性和減少併發症的關注、為心律調節器患者提供的遠端程式設計和遠端醫療服務、新興市場的擴張和不斷上漲的醫療成本、增強的電池技術以延長心律調節器使用壽命,以及加快心律調節器核准的監管支援。預測期內的主要趨勢包括精準植入的電生理學進步、心律調節器數據與電子健康記錄(EHR) 的整合、人工智慧 (AI) 的整合以進行預測性心律調節器維護、心律調節器技術進步(包括小型化)以及遠距遠端醫療和遠端監控。
心臟節律器是一種小型電子設備,它能產生電脈衝來調節心率,並治療心律不整等疾病。這些設備在防止心跳過快或過慢方面發揮著至關重要的作用。
心臟節律器主要分為植入式和外置式。植入式心臟節律器是透過手術植入胸腔的電子設備,可產生電脈衝來調節心率。各種心臟節律器技術包括雙心室、單心室和雙心室系統。這些設備用於治療各種疾病,包括心律不整、心臟傳導阻滯、心房顫動、長QT症候群和鬱血性心臟衰竭。心臟節律器可供最終使用者使用,包括診所、醫院、門診手術中心和心臟護理中心。隨著技術和外科手術的不斷進步,市場也在不斷發展,有助於改善患者照護和治療效果。
2025年春季美國關稅大幅上調及其引發的貿易摩擦對醫療設備產業產生了重大影響,尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價,製造商面臨利潤壓力。監管挑戰使情況更加複雜,因為由於關稅而更換供應商通常需要重新認證醫療設備,導致市場進入延遲。為此,企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。
本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分,該系列提供心臟心律調節器市場統計數據,包括全球市場規模、區域佔有率、心臟心律調節器市場佔有率競爭對手、詳細的心臟心律調節器細分市場、市場趨勢和商業機會,以及在心臟心律調節器行業取得成功所需的數據。這份心臟心律調節器市場研究報告提供了全面的展望,並對產業現狀和未來進行了詳細分析。
未來五年7.1%的預測成長率較我們先前對該市場的預測略有下降,下降幅度為0.1%。下降的主要原因是美國與其他國家之間的關稅影響。這種影響可能會直接影響到美國,導致鋰碘電池電芯和密封鈦外殼的供應鏈中斷,這些電池主要來自中國和墨西哥等主要地區,這可能導致植入手術延誤,並增加心搏過緩治療的成本。
心血管疾病的快速成長是心臟節律器市場的主要驅動力。心血管疾病包括影響心臟和血管的各種疾病,例如心律不整、主動脈疾病、先天性心臟疾病和心臟病發作。為了解決這個日益嚴重的全球健康問題,人們開始採用產生電活動的心臟節律器來治療心血管疾病患者。世界衛生組織 (WHO) 於 2023 年 9 月報告稱,心血管疾病每年將導致 4,100 萬人死亡,佔非傳染性疾病的 74%,凸顯了對心臟治療進步的迫切需求。因此,心血管疾病盛行率的不斷上升預計將推動心臟心律調節器市場的成長。
政府旨在促進醫療保健研究和開發的舉措有望推動心臟心律調節器市場的發展。各級政府部門採取的這些舉措包括旨在應對醫療保健挑戰和促進社會積極變革的行動、計劃和政策。值得注意的是,2022 年,英國政府撥款 2.6 億英鎊(2.7065 億美元)用於加強醫療保健研究和製造。衛生和社會保障部的這項承諾著重於加強臨床研究服務,並支持 NHS主導的診斷和治療方法健康研究。此外,還撥款 6,000 萬英鎊(6,360 萬美元)用於擴大英國的生命科學製造業。這些政府舉措在推動心臟治療和推動心臟心律調節器市場成長方面發揮關鍵作用。
技術創新,尤其是無導線心律調節器的發展,是心臟節律器市場的關鍵趨勢。主要企業正在積極推出創新解決方案,以加強患者照護和市場競爭力。無導線心律調節器是自足式的發電機和電極系統,其顯著優勢在於:比傳統的經靜脈心律調節器體積小90%。透過股靜脈經導管技術植入,無需胸部切口或皮下發電機袋。值得注意的是,2022年1月,總部位於愛爾蘭的醫療設備製造商Medtronic力公司推出了Micra AV經導管起搏系統(TPS),這是一款專為心室和心房之間電傳導受損的患者設計的無導線心律調節器。
心臟心律調節器市場的主要企業正在透過 i2i(設備間)通訊技術等產品進行創新,該技術促進了兩個設備之間的即時通訊。這種 i2i(設備間)通訊技術可實現不同基礎設施系統之間的無縫資料交換,從而提高自動化程度和營運效率。例如,2023 年 11 月,美國醫療設備製造商雅培實驗室推出了 AVEIR DR 系統,用於治療心律不整或延遲的患者。此尖端的雙腔無導線心律調節器系統可為右心房和心室提供同步起搏,確保正常的心律。它透過微創手術植入,減少了恢復時間和併發症。先進的設備植入技術可實現設備之間的即時通訊,協調有效的起搏。這項技術創新代表了心臟健康管理的重大進步。
2022年7月,專注於變革性治療產品的美國公司Orchestra BioMed與Medtronic合作。Medtronic與Orchestra BioMed的合作旨在開發Backbeat心臟神經調節療法(CNT),這是一種潛在的治療高血壓的方案,適用於需要安裝心臟心律調節器的人。此次合作彰顯了Medtronic等領先公司致力於開拓醫療技術進步、促進心臟護理發展的承諾。
心臟心律調節器市場的一些主要企業包括美敦力公司、樂普醫療技術有限公司、波士頓科學公司、Oscor 公司、Osypca Medical GmbH、Zoll Medical Corporation、微創醫療科學公司、庫克集團公司、索林集團、Vitatron & Medical Co.、Cordis 公司、Shree Puptronix Limited、Medico SpA、聖塔尼亞Devices、Cardiostim、Advena Ltd.、Mediana Co.Ltd.、Vimecon GmbH、Cardiac Science Corporation、Greatbatch Medical、Galix Biomedical Instrumentation、南京微創醫療、Cardionovum GmbH。
2024年,北美是心臟節律器市場最大的地區。預計亞太地區將成為預測期內成長最快的地區。心臟節律器市場報告涵蓋亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。
心臟節律器市場報告涉及的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國和美國。
心臟心律調節器市場包括單腔、雙腔和雙心室心律調節器的銷售。該市場的價值指的是“出廠價”,即產品製造商或生產商銷售給其他營業單位(包括下游製造商、批發商、經銷商和零售商)或直接銷售給最終客戶的價值。該市場的產品價值還包括產品製造商提供的任何相關服務。
The cardiac pacemaker is defined by small electronic devices that generate electrical impulses to regulate heartbeats and treat conditions like arrhythmias. These devices play a crucial role in preventing the heart from beating too fast or too slow.
The primary categories of cardiac pacemakers consist of implantable and external variants. Implantable cardiac pacemakers, installed through surgery, are electronic devices generating electrical impulses within the chest to maintain a regular heart rate. Different technologies in cardiac pacemakers encompass biventricular, single-chambered, and dual-chambered systems. These devices find applications in treating various conditions such as arrhythmias, heart blockage, atrial fibrillation, long QT syndrome, and congestive cardiac failure. Cardiac pacemakers serve end-users including clinics, hospitals, ambulatory surgical centers, and cardiac care centers. The market continues to evolve with ongoing advancements in technology and surgical procedures, contributing to improved patient care and outcomes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The cardiac pacemakers market research report is one of a series of new reports from The Business Research Company that provides cardiac pacemakers market statistics, including cardiac pacemakers industry global market size, regional shares, competitors with a cardiac pacemakers market share, detailed cardiac pacemakers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac pacemakers industry. This cardiac pacemakers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cardiac pacemakers market size has grown steadily in recent years. It will grow from $4.73 billion in 2024 to $4.95 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to aging population and the prevalence of cardiovascular diseases, growing awareness of arrhythmias and the need for treatment, investment in research and development for pacemaker innovation, evolving healthcare infrastructure and access to medical devices, and regulatory approvals for novel pacemaker features and technologies.
The cardiac pacemakers market size is expected to see strong growth in the next few years. It will grow to $6.5 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to focus on lead durability and reduction of complications, remote programming and telehealth services for pacemaker patients, expansion of emerging markets and rising healthcare expenditure, enhanced battery technologies for longer pacemaker lifespans, and regulatory support for expedited pacemaker approvals. Major trends in the forecast period include electrophysiology advancements for precision implantation, integration of pacemaker data into electronic health records (ehrs), integration of artificial intelligence (ai) for predictive pacemaker maintenance, advancements in pacemaker technology, including miniaturization, and telemedicine and remote monitoring.
The forecast of 7.1% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for lithium-iodine battery cells and hermetic titanium casings, sourced from key regions such as China and Mexico, which could lead to implantation procedure delays and increased costs for bradycardia treatment.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The surge in cardiovascular diseases is a significant driver for the cardiac pacemaker market. Cardiovascular diseases encompass a range of disorders affecting the heart or blood vessels, including arrhythmias, aorta disease, congenital heart disease, and heart attacks. To address the growing global health concern, cardiac pacemakers, which generate electric activity, are employed in treating patients with cardiovascular diseases. In September 2023, the World Health Organization reported that annually, 41 million deaths, accounting for 74% of non-communicable diseases, were attributed to cardiovascular diseases, highlighting the pressing need for advancements in cardiac care. Consequently, the increasing prevalence of cardiovascular diseases is expected to propel the growth of the cardiac pacemaker market.
Government initiatives aimed at fostering research and development in healthcare are poised to drive the cardiac pacemaker market. These initiatives, undertaken by government authorities at various levels, encompass actions, programs, and policies designed to address healthcare challenges and promote positive societal changes. Notably, in 2022, the UK government allocated £260 million ($270.65 million) in funding to bolster healthcare research and manufacturing. This commitment, from the Department of Health and Social Care, supports NHS-led health research into diagnostics and treatments, with a focus on enhancing clinical research services. Additionally, £60 million ($63.60 million) was earmarked to expand life sciences manufacturing in the UK. Such government initiatives play a pivotal role in advancing cardiac care and fueling the growth of the cardiac pacemaker market.
Innovations, particularly the development of leadless cardiac pacemakers, emerge as a key trend in the cardiac pacemaker market. Major players in the industry are actively introducing innovative solutions to enhance patient care and market competitiveness. The leadless pacemaker, a self-contained generator and electrode system, offers significant advantages, being 90% smaller than traditional transvenous pacemakers. Its implantation via a femoral vein transcatheter technique eliminates the need for chest incisions and subcutaneous generator pockets. Notably, in January 2022, Medtronic PLC, an Ireland-based medical devices company, introduced the Micra AV Transcatheter Pacing System (TPS), a leadless pacemaker designed for patients with compromised electrical communication between the heart's ventricle and atria, addressing a critical aspect of cardiac health with cutting-edge technology.
Major companies in the cardiac pacemaker market are innovating products such as i2i communication technology, which facilitates real-time communication between two devices. This i2i (infrastructure-to-infrastructure) communication technology allows seamless data exchange between different infrastructure systems, enhancing automation and operational efficiency. For example, in November 2023, Abbott Laboratories, a US-based medical device company, launched the AVEIR DR System to treat patients with abnormal or slow heart rhythms. This cutting-edge dual-chamber leadless pacemaker system provides synchronized pacing for both the right atrium and ventricle, ensuring a proper heart rhythm. It is implanted using a minimally invasive procedure, which decreases recovery time and complications. The advanced implant-to-implant technology enables real-time communication between the devices, coordinating effective pacing. This innovation marks a significant advancement in heart health management.
In July 2022, Orchestra BioMed, a US-based company specializing in transformative therapeutic products, entered into a collaboration with Medtronic. The partnership between Medtronic and Orchestra BioMed aims to develop BackBeat Cardiac Neuromodulation Therapy (CNT), a potential therapeutic solution for hypertension in individuals requiring a cardiac pacemaker. This collaboration underscores the commitment of major players, such as Medtronic, to pioneer advancements in healthcare technology and contribute to the evolution of cardiac care.
Major companies operating in the cardiac pacemakers market include Medtronic plc, Lepu Medical Technology Co., Abbott Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, Oscor Inc., Osypca Medical GmbH, Zoll Medical Corporation, MicroPort Scientific Corporation, Cook Group Incorporated, Sorin Group, Vitatron & Medical Co., Cordis Inc., Shree Pacetronix Limited, Medico SpA, St. Jude Medical, LivaNova PLC, Schiller AG, BTL Industries Inc., CCC Medical Devices, Cardiostim, Advena Ltd., Mediana Co. Ltd., Vimecon GmbH, Cardiac Science Corporation, Greatbatch Medical, Galix Biomedical Instrumentation, Nanjing MicroPort Medical, Cardionovum GmbH
North America was the largest region in the cardiac pacemakers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac pacemakers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the cardiac pacemakers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The cardiac pacemaker market consists of sales of single chamber, dual chamber and Biventricular pacemakers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cardiac Pacemakers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cardiac pacemakers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cardiac pacemakers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiac pacemakers market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.